Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961849 | 1.00 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL8527609 | 1.00 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| Water SCHEMBL29655402 | 0.99 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL31453800 | 0.94 | OPRM1 (0.40) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30974040 | 0.92 | OPRM1 (0.42) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30254475 | 0.92 | OPRM1 (0.39) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30997434 | 0.91 | MME (0.38) | MMECD274PDCD1LG2OPRM1OPRD1 | |
| SCHEMBL8437182 | 0.91 | MME (0.37) | MMEECE1CA2CA1 | |
| SCHEMBL8437180 | 0.91 | MME (0.37) | MMEECE1CA2CA1 | |
| SCHEMBL29794242 | 0.91 | MME (0.36) | MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260085097-A1 | DARPIN-CONTAINING COMPOSITIONS AND METHODS THEREOF | TEXAS A & M UNIV SYS (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4626911-A1 | RECOMBINANT POLYPEPTIDE | Humble Bee Limited (NZ) | 2025-10-08 | — | — | EP | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| CN-108610418-B | Anti-complement C1s antibodies and uses thereof | 美国比奥维拉迪维股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115243713-A | Methods and compositions for delivering modified lymphocyte aggregates | 埃克苏马生物技术公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115212289-A | Probiotic active peptide composition and application thereof | 上海朗泰凯尔生物技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-08-25 | — | — | US | disclosed |
| WO-2022169520-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | MME 2240/4885ECE1 4230/4885CD274 3811/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | MME 522/4885ECE1 2597/4885CD274 4224/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | MME 1131/4885ECE1 3158/4885CD274 3811/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MME 2240/4885ECE1 4230/4885CD274 3811/4885 |
| US-20260085097-A1 | DARPIN-CONTAINING COMPOSITIONS AND METHODS THEREOF | FMNL1, ACTL6A, ANKK1 | MME 493/4885ECE1 2563/4885CD274 3159/4885 |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | MME 2240/4885ECE1 4230/4885CD274 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.